Carla Hills - Gilead Sciences Independent Director

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>GS</div>
GILD -- USA Stock  

Report: 4th of August 2020  

  Director
Ambassador Carla A. Hills is no longer Independent Director of Gilead Sciences Inc. Since 1993 she has served as the Chair and Chief Executive Officer of Hills Company a firm providing advice to U.S. businesses on investment trade and risk assessment issues outside the United States. Mrs. Hills serves on the international advisory board of J.P. Morgan Chase. She is CoChair of the Council on Foreign Relations Chair of the National Committee on U.S.China Relations and CoChair of the InterAmerican Dialogue and of the International Advisory Board of the Center for Strategic and International Studies. Mrs. Hills is also a member of the Executive Committee of the Peterson Institute for International Economics and of the Trilateral Commission. Mrs. Hills served as U.S. Trade Representative from 1989 to 1993 and was principal advisor on international trade to President George H. W. Bush. Under President Gerald R. Ford she served as Secretary of Housing and Urban Development.
Age: 80    MBA    
650 574-3000  www.gilead.com

Carla Hills Latest Insider Activity

Gilead Sciences Management Efficiency

Gilead Sciences has return on total asset (ROA) of 5.36 % which means that it generated profit of $5.36 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 22.29 %, meaning that it created $22.29 on every $100 dollars invested by stockholders. Gilead Sciences management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 9.18. The current year Return on Average Assets is expected to grow to 0.14Gilead Sciences Total Assets Per Share are projected to increase significantly based on the last few years of reporting. The past year's Total Assets Per Share were at 48.68. The current year Asset Turnover is expected to grow to 0.43, whereas Current Assets are forecasted to decline to about 26.3 B. The current year Tax Liabilities is expected to grow to about 6.6 B, whereas Total Liabilities is forecasted to decline to about 34.3 B.
The company currently holds 24.1 B in liabilities with Debt to Equity (D/E) ratio of 1.09, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 2.98, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Manvinder BangaGlaxoSmithKline PLC
2016
Alan LacyBristol Myers Squibb
2008
Eugene WashingtonJohnson Johnson
2012
Thomas GlocerMerck Company
2007
Nazneen RahmanAstrazeneca PLC
2017
Steven MayerGrifols S A
2016
Carina LazaroGrifols S A
2015
Ronald WilliamsJohnson Johnson
2011
Peter WendellMerck Company
2003
Togo WestBristol Myers Squibb
2015
Weiying WangAstrazeneca PLC
2019
Hubert JolyJohnson Johnson
2019
Michel DemareAstrazeneca PLC
2019
Deryck MaughanGlaxoSmithKline PLC
2013
Mary BeckerleJohnson Johnson
2015
Juan LucianoEli Lilly And
2019
William KaelinEli Lilly And
2012
Cornelia BargmannAstrazeneca PLC
2015
Jose BaselgaBristol Myers Squibb
2018
Inigo MardonesGrifols S A
2017
Christopher ToveyGW Pharmaceuticals Plc
2012

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 11800 people.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,800 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human Resources
John McHutchison, Executive Vice President - Clinical Research
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations
John Martin, Chairman and CEO
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Gayle Wilson, Independent Director
Daniel ODay, Chairman of the Board, CEO
Jacqueline Barton, Director
Brett Pletcher, Executive VP and General Counsel
William Lee, Executive Vice President - Research
John Madigan, Independent Director
Martin Silverstein, Executive Vice President - Strategy
Kevin Lofton, Independent Director
Paul Carter, Executive Vice President - Commercial Operations
Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary
Diana Brainard, Senior Vice President HIV and Emerging Viral Infections
Carla Hills, Independent Director
John Cogan, Lead Independent Director
John Milligan, Pres and COO
Nicholas Moore, Independent Director
James Meyers, Executive Vice President - Worldwide Commercial Operations
Katie Watson, Executive Vice President of Human Resources
Kelly Kramer, Director
Johanna Mercier, Chief Commercial Officer
Jyoti Mehra, Executive Vice President of Human Resources
Laura Hamill, Executive Vice President - Worldwide Commercial Operations
Robin Washington, CFO and Executive VP
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD
Per WoldOlsen, Independent Director
Harish Manwani, Director
Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing
Kevin Young, COO
Etienne Davignon, Independent Director
Richard Whitley, Independent Director

Stock Performance Indicators

Did you try this?

Run ETF Directory Now

   

ETF Directory

Find actively-traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page